Literature DB >> 12364468

Overexpression of wild-type activin receptor alk4-1 restores activin antiproliferative effects in human pituitary tumor cells.

Daniel C Danila1, Xun Zhang, Yunli Zhou, Jaafar N Sleiman Haidar, Anne Klibanski.   

Abstract

Activin is a member of the TGF beta family of cytokines involved in the control of cell proliferation. We have previously shown that the majority of clinically nonfunctioning pituitary tumors do not respond to activin-induced growth suppression. Human pituitary tumors specifically express alternatively spliced activin type I receptor Alk4 mRNAs, producing C-terminus truncated isoforms designated Alk4-2, 4-3, and 4-4. However, it is not known whether these truncated activin receptors suppress activin effects on cell proliferation in human pituitary cells. Therefore, we investigated activin signaling in a human pituitary tumor cell line, HP75, derived from a clinically nonfunctioning pituitary tumor. HP75 cells express activin A mRNA and secrete activin A, as measured by ELISA and a functional bioassay. TGF beta administration decreases the proliferation of HP75 cells, suggesting that the signaling pathway shared by TGF beta and activin is functional in this cell line. However, activin neither inhibits cell proliferation nor stimulates reporter gene expression in HP75 cells, indicating that activin signaling is specifically blocked at the receptor level. HP75 cells express all truncated activin type I receptor Alk4 isoforms, as determined by RT-PCR. Because truncated Alk4 receptor isoforms inhibit activin signaling by competing with the wild-type receptor for binding to activin type II receptors, we hypothesized that overexpression of wild-type activin type I receptor will restore activin signaling. In HP75 cells, cotransfection of the wild-type activin type I receptor Alk4-1 expression vector increases activin-responsive reporter activity. Furthermore, transfection with wild-type activin receptor type I results in activin-mediated suppression of cell proliferation. These data indicate that truncated Alk4 isoforms interfere with activin signaling pathways and thereby may contribute to uncontrolled cell growth. Overexpression of the wild-type Alk4-1 receptor restores responsiveness to activin in human pituitary tumor-derived cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12364468     DOI: 10.1210/jc.2002-020527

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Loss of ACVRIB leads to increased squamous cell carcinoma aggressiveness through alterations in cell-cell and cell-matrix adhesion proteins.

Authors:  Holli A Loomans; Shanna A Arnold; Kate Hebron; Chase J Taylor; Andries Zijlstra; Claudia D Andl
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

Review 2.  Activin receptor-like kinases: a diverse family playing an important role in cancer.

Authors:  Holli A Loomans; Claudia D Andl
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

3.  The Local Control of the Pituitary by Activin Signaling and Modulation.

Authors:  Louise M Bilezikjian; Wylie W Vale
Journal:  Open Neuroendocrinol J       Date:  2011-01-01

4.  Conditional activin receptor type 1B (Acvr1b) knockout mice reveal hair loss abnormality.

Authors:  Wanglong Qiu; Xiaojun Li; Hongyan Tang; Alicia S Huang; Andrey A Panteleyev; David M Owens; Gloria H Su
Journal:  J Invest Dermatol       Date:  2010-12-30       Impact factor: 8.551

5.  Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.

Authors:  Fancai Zeng; Guoxiong Xu; Tiejun Zhou; Chengwan Yang; Xinyan Wang; Chun Peng; Hong Zhou
Journal:  Med Oncol       Date:  2011-11-16       Impact factor: 3.064

6.  Testes-specific protease 50 promotes cell proliferation via inhibiting activin signaling.

Authors:  Z-B Song; P Wu; J-S Ni; T Liu; C Fan; Y-L Bao; Y Wu; L-G Sun; C-L Yu; Y-X Huang; Y-X Li
Journal:  Oncogene       Date:  2017-06-26       Impact factor: 9.867

7.  MicroRNA profile indicates downregulation of the TGFβ pathway in sporadic non-functioning pituitary adenomas.

Authors:  Henriett Butz; István Likó; Sándor Czirják; Péter Igaz; Márta Korbonits; Károly Rácz; Attila Patócs
Journal:  Pituitary       Date:  2011-06       Impact factor: 4.107

8.  Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma.

Authors:  Katarina Pinjusic; Olivier Andreas Dubey; Olga Egorova; Sina Nassiri; Etienne Meylan; Julien Faget; Daniel Beat Constam
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

9.  Regulation of cell growth and expression of 7B2, PC2, and PC1/3 by TGFbeta 1 and sodium butyrate in a human pituitary cell line (HP75).

Authors:  Ikuo Kobayashi; Long Jin; Katharina H Ruebel; Jill M Bayliss; Oka Hidehiro; Ricardo V Lloyd
Journal:  Endocrine       Date:  2003-12       Impact factor: 3.633

Review 10.  Perspectives of small molecule inhibitors of activin receptor‑like kinase in anti‑tumor treatment and stem cell differentiation (Review).

Authors:  Xueling Cui; Shumi Shang; Xinran Lv; Jing Zhao; Yan Qi; Zhonghui Liu
Journal:  Mol Med Rep       Date:  2019-04-30       Impact factor: 2.952

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.